Fig. 1: Isolation of three non-Omicron NAbs from COVID-19 convalescent individuals. | Cell Discovery

Fig. 1: Isolation of three non-Omicron NAbs from COVID-19 convalescent individuals.

From: Combating the SARS-CoV-2 Omicron (BA.1) and BA.2 with potent bispecific antibodies engineered from non-Omicron neutralizing antibodies

Fig. 1

a Binding of GW01, 16L9, and 4L12 to the SARS-CoV-2 RBD, Omicron RBD and trimer in an ELISA. REGN10987 was used as a control. b Neutralizing activities of GW01, 16L9, and 4L12 and their combinations against pseudotyped SARS-CoV-2 and its variants Alpha, Beta, Gamma, Delta, and Omicron, as well as sarbecoviruses. S309 was used as a positive control. c Binding of 4L12, 16L9, and RGN10987 to the SARS-CoV-2 RBD in competition with GW01, as measured by BLI.

Back to article page